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this intervention is incompletely defined.3 Steroid
administration has been suggested to inhibit ischemia-
reperfusion injury and to reduce the inflammatory
response associated with CPB,10-13 but clinical benefits
have not been conclusively demonstrated. Hence
steroid pretreatment remains controversial. Moreover, it
was suggested that steroid-treated patients might have
greater blood endotoxin levels during CPB.14
This prospective, randomized study was designed to
explore the possible relationship between steroid pre-
treatment and the degree of endotoxin release during
clinical CPB. To help to define the source of endotoxin,
we measured endotoxin levels in both venae cavae.
Patients and methods
In a 2-month period, 20 patients undergoing CPB for coro-
nary artery bypass grafting (CABG) or valvular operations
were randomly divided into 2 groups receiving steroids or
placebo. The study protocol was approved by the institutional
review board. Written informed consent forms were obtained
in all cases. Patients undergoing a potentially short duration of
CPB such as for CABG of fewer than 3 grafts, those under-
going a redo or an emergency procedure, those who had infec-
tious disease before the operation, and those who had used
steroids in the preoperative period were not included. Hence
12 patients underwent minimally invasive direct CABG and
another 65 patients who underwent CPB in the same period
and who did not meet the inclusion criteria were excluded
from the final study. For those patients who met the inclusion
T ransient endotoxemia during clinical cardiopulmonarybypass (CPB) has been widely recognized.1-3 The
phenomenon has been suggested to play an important role
by increasing the generation of proinflammatory cyto-
kines such as tumor necrosis factor–a 4 and may subse-
quently result in postoperative complications.5,6 The
source of endotoxin during CPB, however, is still unclear.
It has been suggested that endotoxin may be mainly
released from the gut, because of increased intestinal per-
meability associated with splanchnic hypoperfusion dur-
ing CPB.7-9 No direct evidence so far supports such an
attractive hypothesis in the clinical setting.3
Corticosteroids have been used during cardiac opera-
tions with CPB for many years, but the mechanism of
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criteria, the type of treatment was determined by opening a
sealed envelope prepared in advance. The preoperative char-
acteristics in the 2 groups were similar.
All patients received a similar balanced anesthetic regimen,
including sufentanil and midazolam. Relaxation was achieved
with pancuronium. Cefuroxime (Zinacef; GlaxoWellcome
Belgium) was given intravenously for prophylaxis at a dose of
1.5 g at induction of anesthesia, followed by 1.5 g every 12
hours for 48 hours. All patients received aprotinin (Trasylol;
Bayer, Leverkusen, Germany) intravenously at a dose of 280
mg within 30 minutes of the beginning of the operation, 280
mg added to the prime of the circuit when starting CPB, and
70 mg/h during CPB. Patients in the steroid pretreatment
group (S-group) received a 30 mg/kg dose of methylpred-
nisolone (Solu-Medrol; Pharmacia & Upjohn, Kalamazoo,
Mich) during induction of anesthesia. The other 10 patients in
the placebo group (NS-group) did not receive steroids before,
during, or after CPB.
The extracorporeal circuit consisted of a roller pump
(Stöckert Instrumente GmbH, Munich, Germany) and a mem-
brane oxygenator (Optima; Cobe Cardiovascular Inc, Arvada,
Colo). Standard systemic heparinization (3 mg/kg) was
accomplished and an activated clotting time of more than 480
seconds was maintained during CPB. The pump flow was set
at 2.4 L/min per square meter. All patients were cooled to
between 30°C and 32°C. Heparin was neutralized with prot-
amine sulfate on discontinuation of CPB.
Blood samples for the measurements of endotoxin were
collected simultaneously from the superior vena cava (SVC)
through a standard central venous catheter introduced via the
internal jugular vein and from inferior vena cava (IVC)
through a femoral venous catheter that was inserted with flu-
oroscopic guidance after induction of anesthesia. The tips of
both catheters were placed about 1.5 cm away from the
respective caval opening to the right atrium. After the opera-
tion, their positions were confirmed again by radiography in
the intensive care unit (ICU). The femoral venous catheter
was withdrawn 2 hours after the end of CPB.
The blood sampling schedule was as follows: (1) just
before heparin administration; (2) 5 minutes after the onset of
CPB but before aortic crossclamping; (3) 50 minutes after the
onset of CPB; (4) 5 minutes after aortic declamping; (5) at the
end of CPB; and (6) 1 hour, (7) 2 hours, and (8) 20 hours after
the end of CPB (except for IVC samples). Samples were col-
lected in endotoxin-free tubes (EndoTube ET, with sodium
heparin 120 IU; Chromogenix AB, Mölndal, Sweden), imme-
diately cooled to 4°C, and centrifuged (2800g for 6 minutes
at 4°C). Plasma was stored at –20°C until assay.
Postoperative serum creatine kinase MB and lactate values
were measured every 12 hours within 24 hours. Postoperative
blood losses, duration of mechanical ventilation, and the
length of ICU stay were also recorded. The ICU staff was
blinded as to the pretreatment of steroids.
Plasma endotoxin levels were measured with the Limulus
Fig 1. Endotoxin levels in SVC and IVC blood in patients undergoing CPB with (S-group, n = 10) or without (NS-
group, n = 10) steroid-pretreatment. Data are medians and interquartile ranges. For sampling time points, see text.
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amebocyte lysate test (Coatest Plasma-Endotoxin; Endosafe
Inc, Charleston, SC). The principle of this assay is that endo-
toxin activates a proenzyme in the Limulus amebocyte lysate.
The activated enzyme split off para-nitro aniline from the
chromogenic substrate S-2423 to produce a yellow color,
which can be determined photometrically at 405 nm. The
end-point method was applied for endotoxin measurement,
with each sample being tested in duplicate. The endotoxin
concentration is presented as picograms per milliliter of plas-
ma, with 1 pg corresponding to 0.012 unit of endotoxin. No
adjustment was made for hemodilution. Laboratory techni-
cians were not aware of the clinical data.
The Mann-Whitney U test was used for comparison of clin-
ical data between 2 groups. Inasmuch as endotoxin values
were not normally distributed, logarithm was applied. Data
transformation was confirmed by the Kolmogorov-Smirnov
test. Multivariate analysis was used to compare endotoxin
levels between groups across time. Unbalanced repeated-
measures models with first-order autoregressive covariance
matrices (BMDP/Dynamic Program 5V, release 7, BMDP
Statistical Software Inc, Los Angeles, Calif) were applied.
The Wilcoxon signed-rank test was also used for comparison
between paired SVC and IVC samples at a specific time point
as appropriate. Clinical data are expressed as mean ± stan-
dard deviation. Endotoxin values are presented as medians
and interquartile ranges.
Results
Four patients in each group underwent combined pro-
cedures, namely, valve replacement with CABG. The
intergroup differences were not statistically significant in
terms of the operative and postoperative variables,
including the levels of creatine kinase MB or lactate and
the duration of mechanical ventilation or ICU stay (Table
I). No patient required re-exploration for bleeding after
the operation. All patients survived the hospital stay.
In both groups of patients, endotoxin levels increased
immediately after the onset of CPB and tended to be
higher in the IVC blood than in the SVC blood (Fig 1).
There was no significant intergroup difference through-
out the study period in SVC endotoxin levels (P = .36
for the group effect) and in their rates of change across
time (P = .76 for the interaction effect). However, IVC
endotoxin levels were significantly higher in the NS-
group than in the S-group (P < .001 for the group
effect), although their trends of change were similar (P
= .28 for the interaction effect).
The paired differences in endotoxin values between
the 2 sites (IVC minus SVC, n = 20) are shown in Fig
2. Endotoxin levels in the IVC blood 5 minutes after
the onset of CPB were higher than in the SVC blood (P
= .03, by Wilcoxon signed-rank test). 
Fig 2. The IVC endotoxin values minus paired SVC values in 20 patients undergoing CPB. Data are medians and
interquartile ranges. For sampling time points, see text.
Table I. Clinical data*
S-group NS-group P value
No. of patients 10 10 /
Male/female 7/3 7/3 /
Age (y) 65 ± 10 65 ± 5 .93
Body surface area (m2) 1.83 ± 0.23 1.87 ± 0.18 .61
Operative data
CPB time (min) 124 ± 26 123 ± 36 .92
Crossclamping time (min) 93 ± 24 94 ± 38 .95
Postoperative data
Peak CK-MB values (IU/L) 36.6 ± 26.7 32.4 ± 16.7 .68
Peak lactate values (mmol/L) 4.3 ± 1.6 2.9 ± 1.4 .06
Total chest tube drainage (mL) 474 ± 264 505 ± 177 .76
Time on ventilator (h) 14 ± 7 18 ± 10 .32
ICU stay (h) 29 ± 9 32 ± 23 .67
CPB: Cardiopulmonary bypass; CK-MB, creatine kinase isoenzyme MB; ICU,
intensive care unit; S/NS-group, patients receiving/not receiving steroid pre-
treatment.
*Data are mean ± standard deviation.
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Discussion
Our study has two findings: First, endotoxin is
released during CPB from the region drained by the
IVC. Second, steroid pretreatment may actually reduce
the release of endotoxin during CPB.
Transient endotoxemia during CPB has been observed
for a decade1,2 and has occasionally been related to unto-
ward effects in patients.5,6 The pathogenesis involved in
this phenomenon, however, is not entirely clear. For
instance, the source of endotoxin during CPB remains to
be fully defined. Two possible factors, exogenous and
endogenous, have been incriminated. On the one hand,
endotoxin has been detected in intraoperatively adminis-
tered fluids.1 On the other hand, nonpulsatile perfusion
during CPB may lead to gut mucosal ischemia, increase
gut permeability,7-9 and result in endotoxin translocation
into portal and systemic circulation. Exogenous endo-
toxin may also be a contributing trigger for gut release of
endotoxin.15,16 Preoperative digestive decontamination
has been suggested to reduce endotoxin levels after
CPB.17 Thus it was logical to speculate that the gut is a
major source of endotoxin during CPB.
However, direct supportive evidence for this hypoth-
esis was lacking. By sampling hepatic venous and
mixed venous blood in 10 patients undergoing CPB,
Andersen and colleagues7 found identical changes in
endotoxin concentrations in the systemic and splanch-
nic circulations. The increase in splanchnic endotoxin
levels was even statistically insignificant compared
with the baseline values.7 The authors7 could not show
a correlation between the elevation of endotoxin levels
and the fall in gastric intramucosal pH. Riddington and
coworkers9 reported increased intestinal permeability
and raised endotoxin levels during CPB but were also
unable to demonstrate any clear relationship between
the two events. In both studies,7,9 intramucosal pH did
not decrease until after the termination of CPB, sug-
gesting that ischemia was not the prime cause for the
increase in intestinal permeability. In addition, some
investigators7,8 found that the increase in gut perme-
ability was related to the duration of CPB, but others
did not.9 A positive correlation between the peak endo-
toxin level and both the duration of CPB and the dura-
tion of aortic crossclamping has been noted by some
investigators,2 but not by others.18
Andersen and colleagues7 reported that the endotoxin
concentrations did not differ in hepatic venous and
mixed venous blood. Although they used a different
analytic technique, including a rocket immunoelec-
trophoretic assay, endotoxin levels in the hepatic venous
blood in their study were similar to those in the IVC
blood in our study. However, endotoxin levels they mea-
sured in the mixed venous blood were relatively high.7
This led us to compare the IVC blood samples with the
premixed blood in the SVC. Our data, showing that
endotoxin levels were higher in blood from the IVC
than from the SVC, support the hypothesis that gut is an
important source of endotoxin under CPB conditions.
The release of endotoxin has been described to be
two-phased, a first peak occurring early after the onset
of CPB and a second one after aortic declamping.4 The
initial phase was explained by the presence of “environ-
mental” exogenous endotoxin in the CPB circuit or
pump prime solution.1,4 However, the higher endotoxin
levels in the IVC blood after the onset of CPB, as
observed in the current study, suggest that the gut may
already be involved in the first part of endotoxin release.
Jansen and associates19 proposed that endotoxin levels
might be related to the degree of initial vasoconstriction
and the degree of the hypo-oncotic state during CPB. It
has also been postulated that the type of flow during
CPB may play a role in inducing endotoxin release.
Some investigators incriminated a nonpulsatile flow,2,4
whereas Watarida and his associates20 reported that pul-
satile flow might reduce endotoxin release.
Nevertheless, the type of flow did not influence endo-
toxin levels during CPB in another randomized trial.21
Andersen and colleagues14 found that endotoxin lev-
els were significantly higher after 90 minutes of CPB
and at the end of CPB in 8 steroid-pretreated patients
undergoing CABG than in control patients. No other
study has been undertaken to confirm or refute this
potentially critical conclusion. The effects of steroid
pretreatment on inflammatory reactions associated
with CPB have been recently reviewed.3,22 Previous
studies documented that steroid treatment can signifi-
cantly inhibit the production of endotoxin-induced
cytokines in patients undergoing CPB, such as tumor
necrosis factor– a , interleukin-6, and interleukin-
8.10-13,22 In a sheep heart transplantation model, steroid
pretreatment has been reported to improve systolic and
diastolic function and hemodynamic stability after
CPB.23 Although not universally applied to clinical
practice, steroid pretreatment has become a fundamen-
tal component of the so-called “fast-track recovery”
protocol and has been suggested to improve postopera-
tive recovery in patients after CPB and to reduce the
length of stay in the ICU and in the hospital.24 In view
of this reasoning, the relationship between steroid pre-
treatment and the degree of the regional release of
endotoxin during CPB needed to be defined. Our results
indicate that steroid pretreatment does not increase, but
may actually reduce endotoxin release during CPB.
However, the findings from this pilot study still need to
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be confirmed in a larger trial, inasmuch as the multiple
comparisons involved in data analysis may overstate the
degree of statistical significance.
The involvement of the complex inflammatory
response in perioperative injury has been recognized in
patients undergoing CPB.3 It was proposed that mesen-
teric ischemia-reperfusion primes circulating neutro-
phils which, when activated by endotoxin, can result in
distant organ damage.25 Although the exact role of
endotoxin in this process remains elusive,26 a low pre-
operative level of immunoglobulin M endotoxin core
antibody has been found to represent an independent
predictor of adverse postoperative outcome in patients
undergoing CPB27 and has been related to postopera-
tive complications after cardiac valve surgery.28
Therefore, on the basis of a better understanding of the
underlying pathogenesis, the development of efficient
therapy aimed at limiting this inflammatory reaction
may improve patient outcome.
We are indebted to Eric M. C. Wong, MA, and Joseph T. F.
Lau, PhD, at Center for Clinical Trials and Epidemiological
Research, The Chinese University of Hong Kong, for their
valuable statistical advice.
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